Clinical Experience With Numeta in Preterm Infants
Status
Conditions
Treatments
Details and patient eligibility
About
The aim of this prospective noninterventional study is to evaluate the clinical application of Numeta® in preterm infants and critically ill neonates in comparison to individualized prescribed parenteral nutrition. With the prescription software Cato-PAN® (by Cato software solutions) exact valid prescriptions for ordering parenteral nutrition solutions for premature infants are compared. Each PN solution is prescribed individually as well as with Numeta. Prescriptions were mirrored with respect to weight, venous approach, total volume and amount of enteral feeding, 24h medication and flipped vice versa. The key nutrient for calculating Numeta prescriptions was protein. The results of PN prescriptions were compared with each other/ESPGHAN recommendations. The investigators hypothesize that nutrimental content of Numeta prescriptions is equal to individually prescribed .parenteral nutrition solutions
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- preterm infants <37 weeks gestational age
- parenteral nutrition therapy
Exclusion criteria
- hypersensitivity to egg, soy or peanut proteins or to any of the active substances
- congenital abnormality of the amino acid metabolism
- pathogenically elevated plasma concentrations of sodium, potassium, magnesium, calcium and/or phosphorous
- severe hyperglycemia
- severe hyperlipidemia
- severe disorders of lipid metabolism characterized by hypertriglyceridemia
Trial design
50 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal